Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents;Tolérance des antidépresseurs inhibiteurs sélectifs de la recapture de la sérotonine chez l'enfant et l'adolescent

Presse Medicale

Volumn 35, Issue 10 II, 2006, Pages 1507-1515

  Bailly, Daniel ^a,b  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; AGITATION; AUTOMUTILATION; BEHAVIOR DISORDER; CHILD; CHILD BEHAVIOR; CLINICAL TRIAL; DATA ANALYSIS; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPIDEMIOLOGICAL DATA; EXCITATION; GENERALIZED ANXIETY DISORDER; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR DEPRESSION; MEDICAL LITERATURE; METHODOLOGY; MONOTHERAPY; MORTALITY; MOTOR PERFORMANCE; OBSESSIVE COMPULSIVE DISORDER; PSYCHOTHERAPY; RESTLESSNESS; REVIEW; RISK FACTOR; SIDE EFFECT; SOCIAL DISABILITY; SOCIAL PHOBIA; SUICIDAL BEHAVIOR;

EID: 33749631556     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74843-6     Document Type: Review

References (49)

1. Cole JO, Bodkin JA. Antidepressant drug side effects. J Clin Psychiatry. 1990; 51 (Suppl 1): 21-6.
2. Riddle MA, King RA, Hardin MT, Scahill L, Ort SI, Chappell P et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol. 1991; 1: 193-8.
3. King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry. 1991; 30: 179-86.
4. Rosenberg DR, Holttum J, Gershon S. Textbook of pharmacotherapy for child and adolescent psychiatric disorders. Brunner/Mazel Publishers, New York. 1994.
5. Bailly D. Efficacité des antidépresseurs inhibiteurs sélectifs de la recapture de la sérotonine chez l'enfant et l'adolescent. Presse Med. 2006; 35: 1293-302.
6. Guile JM. Sertraline-induced behavioral activation during the treatment of an adolescent with major depression. J Child Adolesc Psychopharmacol. 1996; 6: 281-5.
7. Tierney E, Joshi PT, Llinas JF, Rosenberg LA, Riddle MA. Sertraline for major depression in children and adolescents: preliminary clinical experience. J Child Adolesc Psychopharmacol. 1995; 5: 13-27.
8. Garland EJ, Baerg EA. Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol. 2001; 11: 181-6.
9. Leonard HL, March J, Rickler KC, Allen AJ. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997; 36: 725-36.
10. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001; 40: 762-72.
11. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA. 1998; 280: 1752-6.
12. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry. 2001; 40: 222-9.
13. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med. 2001; 344: 1279-85.
14. Wilens TE, Biederman J, Kwon A, Chase R, Greenberg L, Mick E et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol. 2003; 13: 143-52.
15. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ. 2004; 328: 879-83.
16. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. 2003; 290: 1033-41.
17. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004; 363: 1341-5.
18. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002; 41: 1205-15.
19. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997; 54: 1031-7.
20. Wong IC, Besag FM, Santosh PJ, Murray ML. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf. 2004; 27: 991-1000.
21. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006; 63: 332-9.
22. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004; 292: 1969-76.
23. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA. 2004; 292: 807-20.
24. Ohberg A, Vuori E, Klaukka T, Lonnqvist J. Antidepressants and suicide mortality. J Affect Disord. 1998; 50: 225-33.
25. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 2003; 60: 978-82.
26. Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. 2001; 10: 525-30.
27. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005; 62: 165-72.
28. Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry. 2004; 65: 915-8.
29. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004; 292: 338-43.
30. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ. 2005; 330: 389.
31. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990; 147: 207-10.
32. Beasley CM Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ. 1991; 303: 685-92.
33. Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship ? J Clin Psychiatry. 1991; 52: 108-11.
34. Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci. 2003; 28: 331-7.
35. Lapierre YD. Suicidality with selective serotonin reuptake inhibitors: valid claim ? J Psychiatry Neurosci. 2003; 28: 340-7.
36. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005; 330: 385.
37. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005; 330: 396.
38. Aursnes I, Tvete IF, Gaasemyr J, Natvig B. Suicide attempts in clinical trials with paroxetine randomised against placebo. BMC Med. 2005; 3: 14.
39. Leeder JS. Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children. Curr Ther Res. 2001; 62: 900-12.
40. Leeder JS. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today. 2004; 9: 567-73.
41. Shulman R. The serotonin syndrome: a tabular guide. Can J Clin Pharmacol. 1995; 2: 139-44.
42. Kutcher SP. Pharmacologic treatment of depressive disorders. In: Child and adolescent psychopharmacology. Kutcher SP ed. WB Saunders, Philadelphia. 1997; 180-1.
43. Healy D. Side effects of antidepressants. In: Psychiatric drugs explained. Healy D ed. Churchill Livingstone, Edinburgh. 2001; 70-84.
44. Nelson JC. Combined treatment strategies in psychiatry. J Clin Psychiatry. 1993; 54 (Suppl 9): 55-6.
45. Pollack MH. Innovative uses of benzodiazepines in psychiatry. Can J Psychiatry. 1993; 38 (Suppl 4): S122-6.
46. Smith WT, Londborg PD, Glaudin V, Painter JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry. 1998; 155: 1339-45.
47. Londborg PD, Smith WT, Glaudin V, Painter JR. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. J Affect Disord. 2000; 61: 73-9.
48. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1998; 37 (Suppl): 27S-45S.
49. Hjalmarsson L, Corcos M, Jeammet P. Indication des inhibiteurs de la recapture de la sérotonine au cours d'un épisode dépressif majeur chez l'enfant et l'adolescent. Encéphale. 2005; 31: 309-16.